Research progress on human immunodeficiency virus-associated pulmonary arterial hypertension
10.12092/j.issn.1009-2501.2022.12.014
- Author:
Shi MENG
1
;
Zhongqun WANG
1
Author Information
1. Department of Cardiology, Affiliated Hospital of Jiangsu University
- Publication Type:Journal Article
- Keywords:
human immunodeficiency virus;
pathogenesis;
pulmonary hypertension;
treatment
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(12):1431-1440
- CountryChina
- Language:Chinese
-
Abstract:
Human immunodeficiency virus-associated pulmonary arterial hypertension (HIV-PAH) is a long-term cardiovascular complication of AIDS patients, with an incidence of about 0.5%. The onset of HIV-PAH is insidious and lack of specific symptoms with poor prognosis. The pathogenesis is complicated while the bystander effect of HIV or the complication of HIV is possible mechanism. Echocardiography is an important diagnostic method and facilitates early screening of patients. At present, there is no specific drug targeted HIV-PAH, and the treatment strategy is to follow the treatment recommendations for idiopathic pulmonary arterial hypertension on the basis of highly active antiretroviral therapy, while the interaction between two types of drugs should be considered. This paper will mainly focus on the pathogenesis and treatment of HIV-PAH.
